Can Hematological Inflammatory Parameters Predict Mortality in Hepatocellular Carcinoma?

Basit Öğe Kaydı
dc.contributor.authorDertli, Ramazan
dc.contributor.authorAsil, Mehmet
dc.contributor.authorBiyik, Murat
dc.contributor.authorKarakarcayildiz, Ahmet
dc.contributor.authorKeskin, Muharrem
dc.contributor.authorGoktepe, Hakan Mevlut
dc.contributor.authorKayar, Yusuf
dc.date.accessioned2024-02-23T13:59:45Z
dc.date.available2024-02-23T13:59:45Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractPurpose Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. Inflammatory and hematological parameters such as neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) provided useful information especially in the diagnosis, treatment, and follow-up of malignancies. In this study, we planned to demonstrate the efficacy of NLR and PLR levels in the evaluation of the prognosis of patients with HCC in our clinic. Material and Methods This study was planned as a prospective observational cohort study. The study included 105 patients with HCC on the base of cirrhosis. Our study group was classified according to Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria at the time of admission. Results The mean age of all cases was 60.6 +/- 12.4 years, and 77 (73.3%) of the patients were male. The mean life expectancy of all patients was 7.7 +/- 4.3 months. During 1-year follow-up, 61 (58.1%) HCC patients died. The mean survival of the patients who died was 4.6 +/- 3.0 months. In our study, patients with NLR > 2.7, patients with PLR > 100.29, BCLC advanced stage, and Okuda advanced stage, and patients who did not meet the Milan criteria had shorter survival duration. NLR > 2.7, BCLC advanced stage, and Child C were determined as independent risk factors affecting mortality. Conclusion There was a strong correlation between NLR-PLR levels and mortality. PLR and NLR levels can be used in conjunction with other staging systems to regulate, monitor, and predict the survival of HCC patients.en_US
dc.identifier.doi10.1007/s12029-020-00448-2
dc.identifier.endpage675en_US
dc.identifier.issn1941-6628
dc.identifier.issn1941-6636
dc.identifier.issue2en_US
dc.identifier.pmid32617832en_US
dc.identifier.scopus2-s2.0-85087507921en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage666en_US
dc.identifier.urihttps://doi.org/10.1007/s12029-020-00448-2
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11311
dc.identifier.volume52en_US
dc.identifier.wosWOS:000545066100001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Gastrointestinal Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNlren_US
dc.subjectPlren_US
dc.subjectHepatocellularcarcinomaen_US
dc.subjectMortalityen_US
dc.titleCan Hematological Inflammatory Parameters Predict Mortality in Hepatocellular Carcinoma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu